Ellex Medical Lasers will spotlight the role of ABiC (ab-interno Canaloplasty) a new minimally invasive glaucoma surgery (MIGS), during a series of events at the Congress of the American Society of Cataract and Refractive Surgery (ASCRS) being held on May 5-9 at the Los Angeles Convention Center in California.
The events will begin with a breakfast symposium, hosted by EyeWorld, on Saturday 6 May from 8:30 am to 9:30 am in room 404 (level 2). The session, moderated by glaucoma specialist Stephen Vold, MD (USA), will feature guest speakers Mahmoud Khaimi, MD (USA) and Mark Gallardo, MD (USA).
A “Speaker Central” event will follow from 10:30 am to 11 am on Saturday 6 and again on Sunday 7 May at the Ellex exhibit (#2039). Here, Drs. Khaimi and Gallardo will share their experience with ABiC, their clinical study findings, and address attendee questions during a “Q&A” session.
Two “Meet the Expert” sessions with Drs. Khaimi and Gallardo will provide an additional opportunity to learn about ABiC on Saturday 6 and Sunday 7 May from 11:00am to 12:00pm and 3:30pm to 4:30pm at the Ellex Exhibit.
ABiC with iTrack
ABiC is a new ab-interno MIGS procedure that utilizes Ellex’s proprietary iTrackTM illuminated microcatheter to circumferentially viscodilate Schlemm’s canal, the collector channels and the trabecular meshwork. Unlike other MIGS procedures, it restores natural aqueous outflow without damaging ocular tissue or leaving behind a foreign body, such as a stent or shunt.
A key challenge faced by glaucoma surgeons using most MIGS procedures is the need to pinpoint the exact location of increased aqueous outflow resistance. However, it is not always possible to do so and there is no way for a surgeon to be sure that all sites of resistance have been located. But by opening up the entire drainage system, ABiCTM eliminates this uncertainty and study data indicates that the ABiCTM approach produces exemplary outcomes.
Specifically, interim results from a 75-eye study by Dr. Gallardo have shown that, on average, ABiCTM achieves a reduction in mean IOP of 39% and a 70% reduction in medication burden at 24 months postoperatively. In 41 patients who underwent ABiCTM as a standalone procedure, there was a total average decrease in IOP of 34% and 43% at 12 months and 24 months respectively. Medication use was also reduced by 60% at 24 months.
For the first time ever, congress attendees will be given the opportunity to learn how to perform ABiC alongside other leading MIGS procedures, such as iStent and XEN, at a MIGS Skills Transfer Wetlab session. The CME-accredited event will take place on Monday 8 May, from 8 am – 10 am in Room 306 AB on level 2 of the LA Convention Center, where Drs Khaimi and Gallardo will teach the key steps of the procedure.
Clinical outcomes seen with ABiC will also be presented during three papers sessions from 1:42 pm to 1:57 pm on Saturday 6 May, with Dr Gallardo sharing results from a 12 month study involving mild-to-moderate and uncontrolled glaucoma patients, and Dr Khaimi highlighting 3 year outcomes with ABiC and results seen when ABiC is used as a standalone treatment versus as an adjunct to cataract surgery.